Greenwich LifeSciences Expands Clinical Trial to Austria
Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, is taking exciting steps in the fight against breast cancer. Recently, they announced the addition of Austria to their FLAMINGO-01 clinical trial, which focuses on GLSI-100, an innovative immunotherapy aimed at preventing breast cancer recurrences. This expansion comes as a part of their ongoing Phase III clinical trial initiative.
Approval of the Trial in Austria
The company has successfully secured approval from European regulators, officially adding Austria to the list of countries participating in the FLAMINGO-01 trial. This list already includes nations like Spain, France, Germany, Italy, Poland, Romania, Ireland, Portugal, and Belgium, as well as the United States.
Impact of Breast Cancer in Austria
Recent statistics reveal that breast cancer continues to pose significant health challenges in Austria. According to data from the European Cancer Information System, over 6,070 new cases of breast cancer were diagnosed in the country in a recent year, accounting for around 28% of all female cancer diagnoses. Furthermore, breast cancer is the leading cause of cancer-related fatalities among women in Austria, with 1,789 deaths attributed to the disease.
Collaboration with Local Healthcare Institutions
CEO Snehal Patel shared that they are collaborating with principal investigators at the Ordensklinikum Linz in Upper Austria. The clinical site expressed interest in participating in the FLAMINGO-01 trial after patients sought opportunities to join the study. The company has recently been conducting training activities at the Linz site, aiming to get it activated shortly and considering further site developments in Vienna and Salzburg.
Understanding the FLAMINGO-01 Trial and GLSI-100
The FLAMINGO-01 trial, listed under NCT05232916, is designed to assess the safety and effectiveness of GLSI-100 (composed of GP2 + GM-CSF). This treatment targets patients diagnosed with HER2 positive breast cancer who have undergone surgery and experienced residual disease or a high-risk pathological complete response. The trial involves various clinical sites across the United States and Europe and aims to expand its reach to 150 locations globally.
Trial Design and Objectives
Within this double-blinded study, approximately 500 patients with the HLA-A*02 marker will be randomly assigned to receive either GLSI-100 or a placebo, with a third arm treating up to 250 patients with other HLA types exclusively with GLSI-100. The goal is to determine a hazard ratio of 0.3 concerning invasive breast cancer-free survival, necessitating a collection of 28 events for meaningful analysis. An interim review for superiority and futility will be conducted as soon as half of these events—14—are recorded, ensuring the study maintains a robust statistical power.
Information on Breast Cancer and HER2 Positivity
Breat cancer remains a predominant health concern, with one in eight women in the U.S. expected to receive an invasive breast cancer diagnosis throughout their lives. There are around 300,000 new cases each year, alongside 4 million survivors. The HER2 protein, crucial in cell signaling and cancer growth, is present in about 75% of breast cancer cases, categorized by expression levels ranging from low to high.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is dedicated to revolutionizing breast cancer treatment through the development of GP2, an immunotherapy aimed at preventing recurrences in patients post-surgery. By initiating the Phase III clinical trial, FLAMINGO-01, the company is on a promising path toward improved patient outcomes. For additional details about Greenwich LifeSciences and their innovative approaches to cancer treatment, please visit their official website.
Frequently Asked Questions
What is the FLAMINGO-01 trial?
The FLAMINGO-01 trial is a Phase III clinical study testing GLSI-100, aimed at preventing breast cancer recurrence in specific patients.
What significance does Austria's inclusion hold?
Austria's inclusion broadens the trial's geographical reach, allowing more patients to participate and receive potentially life-saving treatment.
What is GLSI-100?
GLSI-100 is an immunotherapy treatment combining GP2 and GM-CSF, targeting breast cancer patients who have residual disease after surgery.
How many patients are involved in the trial?
The trial aims to enroll approximately 750 patients, divided among various treatment groups.
What is the main goal of the trial?
The primary goal is to evaluate the efficacy of GLSI-100 in improving invasive breast cancer-free survival among participants.
